Table 1. – Baseline characteristics of the patients and controls.
| Controls | Patients with heart failure | p | |
|---|---|---|---|
| Median (Q1-Q3) | Median (Q1-Q3) | ||
| GSK-3β (ng/mL) | 13.91 (5.6 -23.3) | 117.26 (45.39 -223.85) | 0.001*** |
| NT-proBNP (pg/mL) | 92 (78 -102 ) | 660 (291 -1000 ) | 0.001*** |
| LVEF (%) | 55 (55 -57 ) | 44.5 (35 -53.5 ) | 0.001*** |
| hs-CRP (mg/L) | 5 (2 -8.4) | 4.78 (2 -7.05 ) | 0.405 |
| Leukocyte | 9 (7.21 -11.53) | 9.71 (7.21 -11.53) | 0.878 |
| Platelet | 258.5 (225 -311 ) | 281 (237 -333 ) | 0.252 |
| Lymphocyte | 2.23 (1.78 -4.87) | 2.31 (1.5 -3.58) | 0.187 |
| Neutrophil | 7.1 (4.96 -7.77 ) | 6.01 (4.44 -7.77) | 0.330 |
| Creatinine | 0.87 (0.71 -1.01) | 0.77 (0.7 -0.99) | 0.148 |
| eGFR | 82.36 (65 -109 ) | 99.5 (72 -109.5 ) | 0.200 |
| NLR | 2.06 (1.12 -4.02) | 2.32 (1.61 -4.01) | 0.212 |
| PLR | 111.05 (57.7 -150.25) | 123.93 (79.21 -180.99) | 0.069 |
***p<0.001; Mann-Whitney U test. GSK-3β; glycogen synthase kinase 3 beta, NT-proBNP: N-terminal pro-brain natriuretic peptide; LVEF: left ventricular ejection fraction; hsCRP: highly sensitive C reactive protein; eGFR: estimated glomerular filtration rate (mL/min/1.73 m2); NLR: neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio.